대장암 치료제 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the colorectal cancer therapeutics market size is expected to grow from USD 13.61 billion in 2025 to USD 14.25 billion in 2026 and is forecast to reach USD 17.9 billion by 2031 at 4.67% CAGR over 2026-2031.

This report is Segmented by Therapy (Immunotherapy, Chemotherapy, and More), by End User (Hospital, Clinics, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Global Colorectal Cancer Therapeutics Market Trends and Insights

Rising Incidence & Prevalence of Colorectal Cancer

Global incidence is projected to climb nearly 10% in men and 12% in women by 2040, while mortality could rise more than 25%. Asia already reports the highest age-standardized rate at 23.88 per 100,000 population, positioning the region as a vital future revenue pool. Growth in the colorectal cancer therapeutics market aligns with government-led screening expansion, yet sizable populations remain unscreened, sustaining late-stage diagnoses and drug demand. Persistent lifestyle risk factors and aging demographics reinforce long-haul therapy volumes, anchoring the colorectal cancer therapeutics market to a durable patient base.

Breakthroughs in Targeted & Immune-Oncology Modalities

Nivolumab plus ipilimumab delivered 72% 24-month progression-free survival in dMMR metastatic disease versus 14% for chemotherapy. Dostarlimab monotherapy achieved a 100% clinical complete response in locally advanced dMMR rectal cancer, eliminating surgery for every treated patient in a pivotal trial. KRAS G12C regimens such as adagrasib plus cetuximab showed a 34% overall response in refractory settings. These data are resetting treatment algorithms and maintaining premium pricing latitude, intensifying innovation cycles inside the colorectal cancer therapeutics market.

High Cost of Novel Biologics & IO Combinations

Checkpoint regimens frequently exceed USD 100,000 annually, straining payer budgets in price-sensitive systems. Immune-mediated colitis affects up to 8.6% of treated patients, adding unplanned supportive-care outlays. Value-based contracting is gaining traction to align payment with outcomes, a trend that may temper near-term revenue growth for the colorectal cancer therapeutics market.

Other drivers and restraints analyzed in the detailed report include:

1. Expanded Reimbursement for Biomarker-Guided Therapies
2. Microbiome-Modulating Adjuvants Boosting Drug Response
3. Severe Toxicity & QoL Trade-Offs Limiting Compliance

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Chemotherapy sustained a 47.55% colorectal cancer therapeutics market share in 2025, yet immunotherapy is set to capture outsized incremental value through a 14.21% CAGR to 2031. Dostarlimab's 100% response in dMMR rectal cancer is emblematic of evidence rewriting practice guidelines. Targeted inhibitors such as sotorasib and adagrasib are broadening applicability beyond MSI-H tumors, translating biomarker discovery directly into revenue. The colorectal cancer therapeutics market size for immunotherapy is forecast to more than double by 2031 as combination protocols earn first-line status in biomarker-defined cohorts.

Pipeline breadth is now anchored in cell-based modalities and bispecific antibodies. GCC19CART recorded 40% objective responses in heavily pre-treated metastatic cases, illustrating how cellular immunotherapies could lift survival in microsatellite-stable disease. As assays for circulating tumor DNA sharpen minimal-residual-disease detection, adaptive dosing models will extend treatment duration, sustaining spending inside the colorectal cancer therapeutics market.

Complete Report Scope:

• By Therapy
  • Immunotherapy
  • Chemotherapy
  • Targeted Therapy
  • Combination Therapy
• By End User
  • Hospitals and Clinics
  • Cancer Research Centers
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 42.35% of 2025 revenue, supported by CMS coverage of advanced screenings and rapid FDA approvals that compress time from lab to clinic. Regional payers champion biomarker testing, embedding precision therapy into standard of care and reinforcing North American leadership within the colorectal cancer therapeutics market. Academic centers' dense trial portfolios catalyze first-in-class uptake, turning the region into a launchpad for global rollouts.

Asia Pacific is the fastest-growing territory with a 9.46% CAGR. Rising incidence, urbanization-linked risk factors, and stepwise healthcare investment fuel volume expansion. China's updated colorectal guidelines mirror Western precision-medicine standards, an alignment expected to unlock multi-billion-dollar potential in the colorectal cancer therapeutics market. Yet screening penetration remains low; Thailand reports that 58.8% of eligible adults have never undergone a screening test, representing untapped demand for both diagnostics and therapies.

Europe delivers steady growth underpinned by EMA approvals; 28 oncology products gained clearance in 2024, including fruquintinib's progression-free survival advantage in refractory disease. Cost-containment frameworks encour-age biosimilar adoption, redistributing budgets toward high-innovation regimens. Meanwhile, Middle East & Africa and South America build capacity through public-private partnerships that prioritize biosimilars and essential medicines, gradually enlarging their presence in the colorectal cancer therapeutics market.

List of Companies Covered in this Report:

1. Roche
2. Pfizer
3. Bayer
4. Bristol-Myers Squibb
5. Eli Lilly and Company
6. Merck
7. Amgen
8. Takeda Pharmaceuticals
9. Sanofi
10. Teva Pharmaceutical Industries
11. Regeneron Pharmaceuticals
12. Genentech
13. Merck
14. Novartis
15. Abbvie
16. AstraZeneca

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Incidence & Prevalence Of Colorectal Cancer
  • 4.2.2 Breakthroughs In Targeted & Immune-Oncology Modalities
  • 4.2.3 Expanded Reimbursement For Biomarker-Guided Therapies
  • 4.2.4 Microbiome-Modulating Adjuvants Boosting Drug Response
  • 4.2.5 AI-Enabled Early Detection Accelerating Therapy Starts
  • 4.2.6 Biosimilar MAbs Price-Led Adoption In Emerging Markets
• 4.3 Market Restraints
  • 4.3.1 High Cost Of Novel Biologics & IO Combinations
  • 4.3.2 Severe Toxicity & QoL Trade-Offs Limiting Compliance
  • 4.3.3 Narrow MSI-H Pool Curbing Checkpoint-Inhibitor
  • 4.3.4 API Supply-Chain Fragility For Key Chemo Agents
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Therapy
  • 5.1.1 Immunotherapy
  • 5.1.2 Chemotherapy
  • 5.1.3 Targeted Therapy
  • 5.1.4 Combination Therapy
• 5.2 By End User
  • 5.2.1 Hospitals and Clinics
  • 5.2.2 Cancer Research Centers
  • 5.2.3 Others
• 5.3 By Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 South Korea
    • 5.3.3.5 Australia
    • 5.3.3.6 Rest of Asia Pacific
  • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 F. Hoffmann-La Roche Ltd
  • 6.3.2 Pfizer Inc.
  • 6.3.3 Bayer AG
  • 6.3.4 Bristol-Myers Squibb Co.
  • 6.3.5 Eli Lilly and Company
  • 6.3.6 Merck & Co., Inc.
  • 6.3.7 Amgen Inc.
  • 6.3.8 Takeda Pharmaceutical Co. Ltd
  • 6.3.9 Sanofi
  • 6.3.10 Teva Pharmaceutical Industries Ltd
  • 6.3.11 Regeneron Pharmaceuticals Inc.
  • 6.3.12 Genentech Inc.
  • 6.3.13 Merck KGaA
  • 6.3.14 Novartis AG
  • 6.3.15 AbbVie Inc.
  • 6.3.16 AstraZeneca plc

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment